drugset / Trial / NCT02671266

Oxytocin Administration in BDD and OCD

NCT02671266 ↗

Phase 2 Completed 41 enrolled Massachusetts General Hospital
RandomizedCrossoverDouble-blindOther

Summary

The purpose of the current study is to investigate the effect of an acute administration of intranasal oxytocin, relative to placebo, on social cognitive impairments among individuals with body dysmorphic disorder and obsessive-compulsive disorder, compared to healthy controls.

Timeline

Start
2014-12
Primary completion
2017-10
Completion
2017-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxytocin Peptide 24 iu Intranasal